Alterity Therapeutics (ATHE) Retained Earnings (2009 - 2025)

Alterity Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$153.9 million for Q4 2025.

• On a quarterly basis, Retained Earnings fell 6.47% year-over-year to -$153.9 million in Q4 2025; TTM through Dec 2025 was -$153.9 million, a 6.47% decrease from a year earlier, with the FY2025 full-year figure at -$144.7 million, down 2.5% from the prior year.
• Retained Earnings retreated to -$153.9 million in Q4 2025 per ATHE's latest filing, from -$144.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $130.7 million in Q2 2021 and bottomed at -$153.9 million in Q4 2025.
• The 5-year median for Retained Earnings is -$130.8 million (2022), against an average of -$97.0 million.
• Across the five-year window, Retained Earnings surged 229.14% in 2021 and sank 7132.96% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$128.4 million in 2021, then gained by 3.13% to -$124.4 million in 2022, then declined by 5.49% to -$131.3 million in 2023, then slipped by 10.11% to -$144.5 million in 2024, then slipped by 6.47% to -$153.9 million in 2025.
• Per Business Quant, the three latest ATHE Retained Earnings figures stand at -$153.9 million (Q4 2025), -$144.7 million (Q2 2025), and -$144.5 million (Q4 2024).